Riding The OPEC+ Wave: Midstream Energy Plays
OPEC+ is moving forward with its plan to increase oil production to meet summer demand. This creates an opportunity for companies that transport, store, and process the additional crude oil and natural gas.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
OPEC+ has confirmed plans to increase oil production to meet summer demand, creating a direct opportunity for midstream energy companies. These businesses operate the essential infrastructure that transports, stores, and processes oil and gas. When production increases, these companies see higher volumes flowing through their pipelines and facilities, potentially boosting their earnings from increased throughput.
What You Need to Know
This group focuses on midstream energy companies that own critical infrastructure like pipelines, storage terminals, and processing facilities. These businesses generate revenue based on the volume of product they handle, making them well-positioned to benefit from increased oil production. They typically have stable, fee-based business models that can provide steady returns during periods of higher energy activity.
Why These Stocks
These specific companies were handpicked by professional analysts for their strategic positioning in the midstream energy sector. Each operates essential infrastructure that will likely see increased utilization as OPEC+ ramps up production. The selection focuses on companies with strong operational capabilities and the capacity to handle higher volumes of oil and gas flowing through global supply chains.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+23.99%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 23.99% over the next year.
Stocks Rated Buy by Analysts
11 of 16 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
OPEC+ Production Surge
With OPEC+ confirming increased oil production for summer demand, these midstream companies are positioned to handle higher volumes flowing through their infrastructure. More oil means more business for pipeline and storage operators.
Infrastructure Advantage
These companies own the essential pipelines, terminals, and processing facilities that oil must pass through. As production ramps up, their fee-based revenue models could see direct benefits from increased throughput and utilization.
Summer Demand Catalyst
The timing aligns perfectly with peak summer driving season and energy demand. This creates a potential double benefit as both production increases and seasonal consumption patterns support higher activity levels across the energy supply chain.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.